BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 YTD Q2 P&L / Income Statement

BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

10,646,000,000 US dollars

Cost of products sold (excluding amortization expense)

3,184,000,000 US dollars

Gross profit

7,462,000,000 US dollars

Operating expenses

5,183,000,000 US dollars

Operating income (loss)

2,279,000,000 US dollars

Other income (expense), net (calculated)

negative 57,000,000 US dollars

Income (loss) before income taxes

2,222,000,000 US dollars

Income tax expense (benefit)

negative 21,000,000 US dollars

Net income (loss)

2,243,000,000 US dollars

Endoscopy

1,529,000,000 US dollars

Urology

1,330,000,000 US dollars

Neuromodulation

659,000,000 US dollars

Interventional Cardiology & Vascular Therapies

2,577,000,000 US dollars

Watchman

1,014,000,000 US dollars

Electrophysiology

1,821,000,000 US dollars

Cardiac Rhythm Management

1,163,000,000 US dollars

Interventional Oncology & Embolization

551,000,000 US dollars

Undisclosed (calculated)

2,000,000 US dollars

Selling, general and administrative expenses

3,583,000,000 US dollars

Research and development expenses

1,069,000,000 US dollars

Royalty expense

24,000,000 US dollars

Amortization expense

466,000,000 US dollars

Intangible asset impairment charges

0 US dollars

Contingent consideration net expense (benefit)

negative 46,000,000 US dollars

Restructuring net charges (credits)

11,000,000 US dollars

Litigation-related net charges (credits)

76,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to BOSTON SCIENTIFIC CORPORATION: $2.25 B; to noncontrolling interests: −$4.00 M.